David Sánchez-Marín

Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatments by being less toxic and improving the survival of cancer patients. The greatest challenge to their success is the resistance exhibited by cancer patients. However, the potential of microRNAs (miRNAs) for sensitizing molecules to TKIs has been well recognized, with several reports publishing promising results. Nonetheless, this therapeutic window faces challenges and several often-overlooked limitations. One of the most fundamental challenges is selecting the optimal miRNA candidates for clinical trials, as miRNAs are promiscuous and regulate hundreds of targets. In this review, we describe how miRNAs enhance sensitivity to TKIs across various types of cancer. We highlight several challenges and limitations in achieving a successful collaboration between small molecules (TKIs–miRNAs). Our focus is on proposing a workflow to select the most suitable miRNA candidate, recommending several available bioinformatics tools to develop a successful therapeutic partnership between TKIs and miRNAs. We hope that this initial proposal will provide valuable support for future research.

Chikungunya virus (CHIKV) induces an acute infection known as chikungunya fever; however, the persistence of CHIKV infections has been reported. This report investigated the persistence of CHIKV over six months in the cervix of two infected women. The infectious CHIKV was isolated from three samples. Our findings demonstrated the persistence of CHIKV in the cervix, highlighting the importance of evaluating other tissue types.

Long non-coding RNAs (lncRNAs) are non-coding RNAs longer than 200 nucleotides with dynamic regulatory functions. They interact with a wide range of molecules such as DNA, RNA, and proteins to modulate diverse cellular functions through several mechanisms and, if deregulated, they can lead to cancer development and progression. Recently, it has been described that lncRNAs are susceptible to form gene fusions with mRNAs or other lncRNAs, breaking the paradigm of gene fusions consisting mainly of protein-coding genes. However, their biological significance in the tumor phenotype is still uncertain. Therefore, their recent identification opens a new line of research to study their biological role in tumorigenesis, and their potential as biomarkers with clinical relevance or as therapeutic targets. The present study aimed to review the lncRNA fusions identified so far and to know which of them have been associated with a potential function. We address the current challenges to deepen their study as well as the reasons why they represent a future therapeutic window in cancer.